152 related articles for article (PubMed ID: 35197448)
1. SAPCD2 promotes neuroblastoma progression by altering the subcellular distribution of E2F7.
Zhang ZM; Cao HB; Li ZH; Zhuo R; Tao YF; Li XL; Li G; Liao XM; Fang F; Xie Y; Wu D; Wang HR; Wang JW; Chen YL; Yu JJ; Jia SQ; Yang RD; Guo XY; Yang Y; Feng CX; Xu YY; Qian GH; Pan J
Cell Death Dis; 2022 Feb; 13(2):174. PubMed ID: 35197448
[TBL] [Abstract][Full Text] [Related]
2. Targeting the XPO1-dependent nuclear export of E2F7 reverses anthracycline resistance in head and neck squamous cell carcinomas.
Saenz-Ponce N; Pillay R; de Long LM; Kashyap T; Argueta C; Landesman Y; Hazar-Rethinam M; Boros S; Panizza B; Jacquemyn M; Daelemans D; Gannon OM; Saunders NA
Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950445
[TBL] [Abstract][Full Text] [Related]
3. Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression.
Liu B; Shats I; Angus SP; Gatza ML; Nevins JR
J Biol Chem; 2013 Aug; 288(34):24581-9. PubMed ID: 23853115
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
Reimer D; Sadr S; Wiedemair A; Stadlmann S; Concin N; Hofstetter G; Müller-Holzner E; Marth C; Zeimet AG
Clin Cancer Res; 2007 Jan; 13(1):144-51. PubMed ID: 17200349
[TBL] [Abstract][Full Text] [Related]
5. Synergistic functions of E2F7 and E2F8 are critical to suppress stress-induced skin cancer.
Thurlings I; Martínez-López LM; Westendorp B; Zijp M; Kuiper R; Tooten P; Kent LN; Leone G; Vos HJ; Burgering B; de Bruin A
Oncogene; 2017 Feb; 36(6):829-839. PubMed ID: 27452520
[TBL] [Abstract][Full Text] [Related]
6. E2F7, a novel target, is up-regulated by p53 and mediates DNA damage-dependent transcriptional repression.
Carvajal LA; Hamard PJ; Tonnessen C; Manfredi JJ
Genes Dev; 2012 Jul; 26(14):1533-45. PubMed ID: 22802528
[TBL] [Abstract][Full Text] [Related]
7. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
[TBL] [Abstract][Full Text] [Related]
8. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence.
Aksoy O; Chicas A; Zeng T; Zhao Z; McCurrach M; Wang X; Lowe SW
Genes Dev; 2012 Jul; 26(14):1546-57. PubMed ID: 22802529
[TBL] [Abstract][Full Text] [Related]
9. Circ-CCS is identified as a cancer-promoting circRNA in lung cancer partly by regulating the miR-383/E2F7 axis.
Yuan Y; Zhou X; Kang Y; Kuang H; Peng Q; Zhang B; Liu X; Zhang M
Life Sci; 2021 Feb; 267():118955. PubMed ID: 33359669
[TBL] [Abstract][Full Text] [Related]
10. DNA-damage response control of E2F7 and E2F8.
Zalmas LP; Zhao X; Graham AL; Fisher R; Reilly C; Coutts AS; La Thangue NB
EMBO Rep; 2008 Mar; 9(3):252-9. PubMed ID: 18202719
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA DLEU2 promotes the progression of esophageal cancer through miR-30e-5p/E2F7 axis.
Lu T; Wang R; Cai H; Cui Y
Biomed Pharmacother; 2020 Mar; 123():109650. PubMed ID: 31884338
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA PXN-AS1-L promotes the malignancy of nasopharyngeal carcinoma cells via upregulation of SAPCD2.
Jia X; Niu P; Xie C; Liu H
Cancer Med; 2019 Aug; 8(9):4278-4291. PubMed ID: 31173488
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-302a/d inhibits the self-renewal capability and cell cycle entry of liver cancer stem cells by targeting the E2F7/AKT axis.
Ma YS; Lv ZW; Yu F; Chang ZY; Cong XL; Zhong XM; Lu GX; Zhu J; Fu D
J Exp Clin Cancer Res; 2018 Oct; 37(1):252. PubMed ID: 30326936
[TBL] [Abstract][Full Text] [Related]
14. Loss of E2F7 expression is an early event in squamous differentiation and causes derepression of the key differentiation activator Sp1.
Hazar-Rethinam M; Cameron SR; Dahler AL; Endo-Munoz LB; Smith L; Rickwood D; Saunders NA
J Invest Dermatol; 2011 May; 131(5):1077-84. PubMed ID: 21248772
[TBL] [Abstract][Full Text] [Related]
15. E2F7 Is a Potent Inhibitor of Liver Tumor Growth in Adult Mice.
Moreno E; Toussaint MJM; van Essen SC; Bongiovanni L; van Liere EA; Koster MH; Yuan R; van Deursen JM; Westendorp B; de Bruin A
Hepatology; 2021 Jan; 73(1):303-317. PubMed ID: 32259305
[TBL] [Abstract][Full Text] [Related]
16. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer.
Liu J; Li X; Wang M; Xiao G; Yang G; Wang H; Li Y; Sun X; Qin S; Du N; Ren H; Pang Y
Int J Oncol; 2018 Oct; 53(4):1601-1612. PubMed ID: 30066905
[TBL] [Abstract][Full Text] [Related]
17. A novel E2F/sphingosine kinase 1 axis regulates anthracycline response in squamous cell carcinoma.
Hazar-Rethinam M; de Long LM; Gannon OM; Topkas E; Boros S; Vargas AC; Dzienis M; Mukhopadhyay P; Simpson F; Endo-Munoz L; Saunders NA
Clin Cancer Res; 2015 Jan; 21(2):417-27. PubMed ID: 25411162
[TBL] [Abstract][Full Text] [Related]
18. Cyclin F-dependent degradation of E2F7 is critical for DNA repair and G2-phase progression.
Yuan R; Liu Q; Segeren HA; Yuniati L; Guardavaccaro D; Lebbink RJ; Westendorp B; de Bruin A
EMBO J; 2019 Oct; 38(20):e101430. PubMed ID: 31475738
[TBL] [Abstract][Full Text] [Related]
19. E2F7, a novel E2F featuring DP-independent repression of a subset of E2F-regulated genes.
Di Stefano L; Jensen MR; Helin K
EMBO J; 2003 Dec; 22(23):6289-98. PubMed ID: 14633988
[TBL] [Abstract][Full Text] [Related]
20. E2F7 represses a network of oscillating cell cycle genes to control S-phase progression.
Westendorp B; Mokry M; Groot Koerkamp MJ; Holstege FC; Cuppen E; de Bruin A
Nucleic Acids Res; 2012 Apr; 40(8):3511-23. PubMed ID: 22180533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
